ATLANTA, Nov. 21, 2011 /PRNewswire/ -- CryoLife,
Inc. (NYSE: CRY), a leading tissue processing and medical
device company focused on cardiac and vascular surgery, announced
today that it will participate in the upcoming 23rd Annual Piper
Jaffray Health Care Conference on Wednesday,
November 30, 2011 at The New York Palace Hotel in
New York City.
Steven G. Anderson, president and
chief executive officer of CryoLife, Inc., is scheduled to present
at 4:00 p.m. Eastern Time.
CryoLife's live presentation may be accessed through its Web
site, www.cryolife.com, on the Investor Relations page. An
archived copy of the presentation will be available for 90 days on
the same Web site.
About CryoLife
Founded in 1984, CryoLife, Inc. is a leader in the processing
and distribution of implantable living human tissues for use in
cardiac and vascular surgeries throughout the U.S. and Canada. CryoLife's CryoValve® SG pulmonary
heart valve, processed using CryoLife's proprietary SynerGraft®
technology, has FDA 510(k) clearance for the replacement of
diseased, damaged, malformed, or malfunctioning native or
prosthetic pulmonary valves. CryoLife's CryoPatch® SG
pulmonary cardiac patch has FDA 510(k) clearance for the repair or
reconstruction of the right ventricular outflow tract (RVOT), which
is a surgery commonly performed in children with congenital heart
defects, such as Tetralogy of Fallot, Truncus Arteriosus, and
Pulmonary Atresia. CryoPatch SG is distributed in three anatomic
configurations: pulmonary hemi-artery, pulmonary trunk, and
pulmonary branch. CryoLife's BioGlue® Surgical Adhesive is
FDA approved as an adjunct to sutures and staples for use in adult
patients in open surgical repair of large vessels. BioGlue is
also CE marked in the European Community and approved in
Canada and Australia for use in soft tissue repair and
was recently approved in Japan for
use in the repair of aortic dissections. CryoLife, through
its subsidiary Cardiogenesis Corporation, specializes in the
treatment of cardiovascular disease and the sale of devices that
treat severe angina. Its market leading FDA-approved Holmium:
YAG laser system and single use fiber-optic delivery systems are
used to perform a surgical procedure known as Transmyocardial
Revascularization (TMR). CryoLife distributes PerClot®, an
absorbable powder hemostat, in the European Community.
CryoLife's BioFoam™ Surgical Matrix is CE marked in the
European Community for use as an adjunct in the sealing of
abdominal parenchymal tissues (liver and spleen) when cessation of
bleeding by ligature or other conventional methods is ineffective
or impractical.
For additional information about the company, visit CryoLife's
Web site: http://www.cryolife.com.
Contacts:
|
|
CryoLife
D. Ashley Lee
Executive Vice President, Chief
Financial Officer and Chief Operating Officer
Phone: 770-419-3355
|
The Ruth Group
Nick Laudico / Zack
Kubow
646-536-7030 / 7020
nlaudico@theruthgroup.com
zkubow@theruthgroup.com
|
|
|
|
SOURCE CryoLife, Inc.